CA2142811C - Methode de preparation d'un nouveau glucane - Google Patents

Methode de preparation d'un nouveau glucane Download PDF

Info

Publication number: CA2142811C
Authority: CA; Canada
Prior art keywords: glucan; beta; soluble; underivatized; aqueous soluble
Prior art date: 1992-08-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002142811A

Other languages

English (en)

Other versions

CA2142811A1 (fr

Inventor

Spiros Jamas

D. Davidson Easson, Jr.

Gary R. Ostroff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Collaborative Group Ltd

Original Assignee

Collaborative Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-21

Filing date

1993-08-20

Publication date

2006-10-31

1992-08-21 Priority claimed from US07/934,015 external-priority patent/US5622939A/en

1993-08-20 Application filed by Collaborative Group Ltd filed Critical Collaborative Group Ltd

1994-03-03 Publication of CA2142811A1 publication Critical patent/CA2142811A1/fr

2006-10-31 Application granted granted Critical

2006-10-31 Publication of CA2142811C publication Critical patent/CA2142811C/fr

2013-08-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229920001503 Glucan Polymers 0.000 title claims abstract description 333
238000002360 preparation method Methods 0.000 title abstract description 37
108010002352 Interleukin-1 Proteins 0.000 claims abstract description 42
210000001616 monocyte Anatomy 0.000 claims abstract description 32
238000004519 manufacturing process Methods 0.000 claims abstract description 30
230000004936 stimulating effect Effects 0.000 claims abstract description 30
230000000694 effects Effects 0.000 claims abstract description 18
238000000338 in vitro Methods 0.000 claims abstract description 16
230000028993 immune response Effects 0.000 claims abstract description 11
210000000440 neutrophil Anatomy 0.000 claims abstract description 10
230000001627 detrimental effect Effects 0.000 claims abstract description 8
230000003641 microbiacidal effect Effects 0.000 claims abstract description 8
210000001539 phagocyte Anatomy 0.000 claims abstract description 6
238000001727 in vivo Methods 0.000 claims abstract description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 59
208000015181 infectious disease Diseases 0.000 claims description 52
239000000203 mixture Substances 0.000 claims description 48
102000000589 Interleukin-1 Human genes 0.000 claims description 40
238000000034 method Methods 0.000 claims description 36
239000000243 solution Substances 0.000 claims description 29
239000002245 particle Substances 0.000 claims description 25
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 22
230000008569 process Effects 0.000 claims description 22
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
239000011780 sodium chloride Substances 0.000 claims description 18
210000004027 cell Anatomy 0.000 claims description 16
230000003308 immunostimulating effect Effects 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
239000002158 endotoxin Substances 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 11
230000015572 biosynthetic process Effects 0.000 claims description 10
230000035755 proliferation Effects 0.000 claims description 10
230000000638 stimulation Effects 0.000 claims description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
238000003786 synthesis reaction Methods 0.000 claims description 9
230000011132 hemopoiesis Effects 0.000 claims description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
210000002966 serum Anatomy 0.000 claims description 8
239000003513 alkali Substances 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
239000000499 gel Substances 0.000 claims description 7
230000035876 healing Effects 0.000 claims description 7
XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical group CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 claims description 6
239000008121 dextrose Substances 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
239000006071 cream Substances 0.000 claims description 4
235000019253 formic acid Nutrition 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000006210 lotion Substances 0.000 claims description 4
239000002674 ointment Substances 0.000 claims description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
238000000746 purification Methods 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
239000000839 emulsion Substances 0.000 claims description 3
239000002953 phosphate buffered saline Substances 0.000 claims description 3
239000003826 tablet Substances 0.000 claims description 3
230000008876 conformational transition Effects 0.000 claims description 2
238000011534 incubation Methods 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 17
108060008682 Tumor Necrosis Factor Proteins 0.000 claims 12
102000003390 tumor necrosis factor Human genes 0.000 claims 12
230000002708 enhancing effect Effects 0.000 claims 8
230000008439 repair process Effects 0.000 claims 4
206010054094 Tumour necrosis Diseases 0.000 claims 2
238000004113 cell culture Methods 0.000 claims 2
230000003472 neutralizing effect Effects 0.000 claims 2
239000000725 suspension Substances 0.000 claims 2
239000008366 buffered solution Substances 0.000 claims 1
230000007935 neutral effect Effects 0.000 abstract description 138
241001465754 Metazoa Species 0.000 abstract description 13
210000001772 blood platelet Anatomy 0.000 abstract description 13
102000004127 Cytokines Human genes 0.000 abstract description 11
108090000695 Cytokines Proteins 0.000 abstract description 11
241000282412 Homo Species 0.000 abstract description 8
206010037660 Pyrexia Diseases 0.000 abstract description 6
206010061218 Inflammation Diseases 0.000 abstract description 5
230000002607 hemopoietic effect Effects 0.000 abstract description 5
230000001900 immune effect Effects 0.000 abstract description 5
230000004054 inflammatory process Effects 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 4
230000003389 potentiating effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 description 25
206010052428 Wound Diseases 0.000 description 23
238000011282 treatment Methods 0.000 description 21
108700012920 TNF Proteins 0.000 description 20
241000699670 Mus sp. Species 0.000 description 14
230000001965 increasing effect Effects 0.000 description 14
238000001356 surgical procedure Methods 0.000 description 14
238000005119 centrifugation Methods 0.000 description 13
238000000605 extraction Methods 0.000 description 13
239000008103 glucose Substances 0.000 description 11
210000004379 membrane Anatomy 0.000 description 11
239000012528 membrane Substances 0.000 description 11
210000005087 mononuclear cell Anatomy 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
238000002512 chemotherapy Methods 0.000 description 9
239000000872 buffer Substances 0.000 description 8
210000002540 macrophage Anatomy 0.000 description 8
239000000463 material Substances 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
229920002558 Curdlan Polymers 0.000 description 6
239000001879 Curdlan Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 6
229920000392 Zymosan Polymers 0.000 description 6
238000000137 annealing Methods 0.000 description 6
230000002924 anti-infective effect Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
235000019316 curdlan Nutrition 0.000 description 6
229940078035 curdlan Drugs 0.000 description 6
201000010099 disease Diseases 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
210000000987 immune system Anatomy 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
238000001959 radiotherapy Methods 0.000 description 6
239000012981 Hank's balanced salt solution Substances 0.000 description 5
229920001491 Lentinan Polymers 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000001914 filtration Methods 0.000 description 5
208000014674 injury Diseases 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
229940115286 lentinan Drugs 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
-1 sodium hydroxide Chemical class 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000029663 wound healing Effects 0.000 description 5
DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 4
229920002101 Chitin Polymers 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
229920001543 Laminarin Polymers 0.000 description 4
239000005717 Laminarin Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
238000010171 animal model Methods 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
230000007123 defense Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000005227 gel permeation chromatography Methods 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
150000002772 monosaccharides Chemical class 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
230000005855 radiation Effects 0.000 description 4
241000894007 species Species 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000233866 Fungi Species 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
229920000057 Mannan Polymers 0.000 description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
210000002421 cell wall Anatomy 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
238000011026 diafiltration Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
230000007124 immune defense Effects 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000018276 interleukin-1 production Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000037452 priming Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000003393 splenic effect Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000008733 trauma Effects 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 2
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
206010058040 Abdominal sepsis Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
241001478240 Coccus Species 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000235649 Kluyveromyces Species 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
206010067268 Post procedural infection Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
244000288561 Torulaspora delbrueckii Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
238000004820 blood count Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
208000015322 bone marrow disease Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000024203 complement activation Effects 0.000 description 2
230000000536 complexating effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 2
210000003622 mature neutrocyte Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
208000004235 neutropenia Diseases 0.000 description 2
208000015380 nutritional deficiency disease Diseases 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
210000003200 peritoneal cavity Anatomy 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000011552 rat model Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
238000004513 sizing Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000008354 sodium chloride injection Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
206010043554 thrombocytopenia Diseases 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
230000037314 wound repair Effects 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
206010000159 Abnormal loss of weight Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
101150039167 Bex3 gene Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000356408 Candida cloacae Species 0.000 description 1
108010051152 Carboxylesterase Proteins 0.000 description 1
102000013392 Carboxylesterase Human genes 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
206010051914 Cholesterosis Diseases 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
241001489198 Cyberlindnera americana Species 0.000 description 1
241000235646 Cyberlindnera jadinii Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
208000005156 Dehydration Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010015137 Eructation Diseases 0.000 description 1
241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
102100029203 F-box only protein 8 Human genes 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101100334493 Homo sapiens FBXO8 gene Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010029803 Nosocomial infection Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000000114 Pain Threshold Diseases 0.000 description 1
206010033661 Pancytopenia Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000191992 Peptostreptococcus Species 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
208000007541 Preleukemia Diseases 0.000 description 1
241000588770 Proteus mirabilis Species 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
235000018370 Saccharomyces delbrueckii Nutrition 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000194022 Streptococcus sp. Species 0.000 description 1
235000014681 Torulaspora delbrueckii Nutrition 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000003811 acetone extraction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000011882 arthroplasty Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000002032 cellular defenses Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
208000024389 cytopenia Diseases 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
238000011902 gastrointestinal surgery Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000003292 glue Substances 0.000 description 1
230000033687 granuloma formation Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
206010019847 hepatosplenomegaly Diseases 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
208000021760 high fever Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000000091 immunopotentiator Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
244000145841 kine Species 0.000 description 1
208000006443 lactic acidosis Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
244000039328 opportunistic pathogen Species 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000037040 pain threshold Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
108010001062 polysaccharide-K Proteins 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000003672 processing method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
229940055033 proteus mirabilis Drugs 0.000 description 1
244000079416 protozoan pathogen Species 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000037322 slow-wave sleep Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000010186 staining Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002142811A 1992-08-21 1993-08-20 Methode de preparation d'un nouveau glucane Expired - Lifetime CA2142811C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/934,015		1992-08-21
US07/934,015 US5622939A (en)	1992-08-21	1992-08-21	Glucan preparation
PCT/US1993/007904 WO1994004163A1 (fr)	1992-08-21	1993-08-20	Nouvelle preparation de glucanes

Publications (2)

Publication Number	Publication Date
CA2142811A1 CA2142811A1 (fr)	1994-03-03
CA2142811C true CA2142811C (fr)	2006-10-31

Family

ID=26786977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002142811A Expired - Lifetime CA2142811C (fr)	1992-08-21	1993-08-20	Methode de preparation d'un nouveau glucane

Country Status (2)

Country	Link
CA (1)	CA2142811C (fr)
NO (1)	NO950634L (fr)

1993
- 1993-08-20 CA CA002142811A patent/CA2142811C/fr not_active Expired - Lifetime
1995
- 1995-02-20 NO NO950634A patent/NO950634L/no unknown

Also Published As

Publication number	Publication date
NO950634L (no)	1995-04-20
NO950634D0 (no)	1995-02-20
CA2142811A1 (fr)	1994-03-03

Legal Events

Date	Code	Title	Description
2000-06-28	EEER	Examination request

Publication	Publication Date	Title
EP0655921B1 (fr)	2001-12-12	Nouvelle preparation de glucanes
US5532223A (en)	1996-07-02	Use of aqueous soluble glucan preparations to stimulate platelet production
US5504079A (en)	1996-04-02	Method for immune system activation by administration of a β(1-3) glucan which is produced by Saccharomyces cerevisiae strain R4
AU650626B2 (en)	1994-06-30	Method for producing soluble glucans
US5811542A (en)	1998-09-22	Method for producing soluble glucans
US6369216B1 (en)	2002-04-09	Very high molecular weight β-glucans
Di Luzio	1985	Update on the immunomodulating activities of glucans
US7022685B2 (en)	2006-04-04	Very high molecular weight β-glucans
EP0506325B1 (fr)	1997-03-05	Polymères de l'acide guluronique et leur utilisation pour l'inhibition de cytokines
CA2142811C (fr)	2006-10-31	Methode de preparation d'un nouveau glucane
AU679690C (en)	1998-04-23	Novel glucan preparation
EP0611304B1 (fr)	1999-09-15	Utilisation de mannane acetyle (acemannan) dans la regulation des taux de cholesterol dans le serum et pour l'elimination de plaques des vaisseaux sanguins